Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 1997

View Archived Issues

SKB reports novel camptothecin analogues

New cephem antibacterial agents from Takeda

Schering-Plough claims tetrahydrofuran antifungal agents

New steroidal anesthetics from Akzo Nobel

N-oxide antibacterial compounds from Bayer

Cortex claims AMPA receptor modulators for CNS disorders

Synthelabo investigates oxazolidinones

Microcide reports new cephalosporin antibiotics

Pfizer reveals agents for hypercholesterolemia, atherosclerosis

Encouraging results reported for Merck anti-HIV combination

Triple combination therapy dramatically effective in HIV/AIDS

Famvir safe and effective in HIV-infected patients with shingles

Dutch investigators find method of improving t-PA therapy

Pilot trial of folic acid in stroke patients

NutraGenics changes name, receives patent coverage for proprietary technology

FDA clears Orphan Medical wound dressing

Pierre Fabre to market Penederm OTC product

Clinical trials to begin on novel antidepressant from Korean company

Schering Canada and University of Toronto collaborate on Alzheimer research

Candidate compound identified in Pharmacopeia/Berlex collaboration

Nobel Laureate to study bacterial resistance to nisin

Isis commences phase I testing of anti-HIV compound

TpP test accurate, rapid and reliable for early diagnosis of MI

Mylan Laboratories receives FDA approval for generic formulation

Dimethaid files second NDA for topical NSAID

Repligen and Pfizer initiate drug discovery collaboration

Bayer to market Amphotec in Canada

Meperidine generic approved

Terrapin and Sosei commence drug discovery collaboration

Cidofovir highlighted at retroviral conference

Zyflo now available in U.S.

Thalidomide: Forty years later

Potent NK1 antagonist reported by Servier

Mixed CCK-A agonist/CCK-B antagonist from Glaxo Wellcome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...